南京医药 (600713)

Nanjing Pharmaceutical Company Limited

ASH

Tags

SSE 580 IndexSpecial Purpose LoansLow Price-to-Earnings RatioCold Chain LogisticsPharmaceuticals and HealthcareInvestments in Financial InstitutionsContains Convertible BondsWholesaleSmart HealthcareBelow Net Asset ValueHigh Accounts Receivable医药生物Pharmaceutical Commerce

K-Line Chart

No K-line data available

Company NameNanjing Pharmaceutical Group Co., Ltd.
Listing Date1996-07-01
Issue Price5.98RMB
Registered Capital130892.928910k RMB
Legal RepresentativeZhou Jianjun
Registered AddressBuilding 2, No. 55 Andemen Street, Yuhuatai District, Nanjing City, Jiangsu Province
IndustryPharmaceutical Commerce
Main BusinessSales of pharmaceutical products.
Company ProfileNanjing Pharmaceutical Group Co., Ltd. (hereinafter referred to as Nanjing Pharmaceutical or the Company) was founded in 1951 and listed on the Shanghai Stock Exchange in 1996, becoming the first listed company in China's pharmaceutical distribution industry. By the end of 2014, the Company completed a strategic cooperation with the world-class healthcare enterprise Walgreens Boots Alliance (ranked 40th in the Fortune Global 500), becoming the first Sino-foreign cooperative A-share listed company in the industry to implement a mixed-ownership reform (in February 2018, the Company completed another private placement, resulting in state-owned shareholding of 31.44% and foreign shareholding of 13.88%). After years of development, Nanjing Pharmaceutical has grown from a regional single entity into a large-scale, cross-regional, group-based, and networked enterprise. It currently has over 60 subsidiaries and branches, with market coverage extending to Jiangsu, Anhui, Fujian, Hubei, and parts of Yunnan and Sichuan (ranking among the top three in market share in Jiangsu, Anhui, and Fujian provinces). The Company serves over 46,000 customers and has established strong cooperative relationships with the top 50 pharmaceutical suppliers. In 2017, its sales revenue was approximately RMB 27.5 billion, ranking among the top ten in the industry by scale.

Stock Details

1. Key Indicators

  • Total Shares(W): 130892.93
  • Circulating A-Shares(W): 128690.45
  • Earnings Per Share(RMB): 0.3100
  • Net Assets Per Share(RMB): 5.3230
  • Operating Revenue(W RMB): 4113514.19
  • Total Profit(W RMB): 70854.57
  • **Net Profit Attributable to Parent(W RMB) **: 40197.12
  • Net Profit Growth Rate(%): -9.03
  • Weighted Return on Equity(%): 5.7900
  • Operating Cash Flow Per Share(RMB): -3.8020
  • Undistributed Profit Per Share(RMB): 2.1619
  • Capital Reserve Per Share(RMB): 1.8752

2. Main Business

The main business covers:

  • Investment and operation of new industrialization projects
  • Venture capital
  • Industrial investment
  • Asset operation, capital operation, non-performing asset disposal
  • Asset entrusted operation
  • Enterprise consulting
  • Project development
  • Property management
  • Financial advisory

3. Company Basic Information

  • Company Name: Nanjing Pharmaceutical Co., Ltd.
  • Listing Date: 1996-07-01
  • Industry: Pharmaceutical Commerce
  • Address: Building 2, No. 55 Andemen Street, Yuhuatai District, Nanjing City, Jiangsu Province
  • Website: https://www.njyy.com
  • Company Profile: The company was jointly established by Nanjing Pharmaceutical Company and three other entities in 1993. Initially, it converted the sponsors' net assets and cash investments into 28.2574 million state shares and 2.5 million legal person shares. It also privately placed 30 million legal person shares and 1.5 million employee shares. After the initial public offering on June 7, 1996, the total shares at listing were 83.0174 million. The 1.5 million internal employee shares were scheduled to become tradable three years after the public shares were listed.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Nanjing Xin Gong Investment Group Co., Ltd. General Legal Person 57820.73 44.93
2 Alliance Healthcare Asia Pacific Limited General Legal Person 14455.74 11.23
3 Jilin Aodong Pharmaceutical Group Co., Ltd. General Legal Person 3015.97 2.34
4 Orient Hongzhong CSI Orient Hongzhong Dividend Low Volatility Index Securities Investment Fund Class A Fund 811.53 0.63
5 Hong Kong Securities Clearing Company Ltd. Northbound Capital 775.91 0.60
6 Invesco Great Wall CSI Shanghai-Hong Kong-Shenzhen Dividend Growth Low Volatility Index Securities Investment Fund 317.23 0.25

5. Concept Sectors

  • Convertible Bonds
  • Smart Healthcare
  • Cold Chain Logistics
  • Financial Holdings
  • Low P/E Ratio
  • Below Net Asset Value
  • High Accounts Receivable
  • Special Loans
  • SSE 580

Remarks

  • Data update date: 2025-09-30
  • Data source: Public market information